Chiltern International Limited (Chiltern), a global contract research organization (CRO) announced a strategic partnership with endpoint. With this investment, Chiltern becomes a minority shareholder in the company established in April 2009.
Glenn Kerkhof, Chiltern CEO, stated, “Chiltern’s decision to invest in endpoint is representative of our commitment to seek collaborations which connect Chiltern and our clients with leading edge solutions as well as our belief in the technology that endpoint has developed.”
PULSE, endpoint’s configurable system that allows users to design and deploy clinical trial IRT systems, was launched in January of this year. PULSE designs systems that can be accessed via the phone, web, or mobile device.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.